NextCure, Inc. Enters At-the-Market Offering Agreement

NextCure, Inc. has entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, allowing the company to sell up to $14.5 million of its common stock. Sales will occur from time to time based on market conditions and the company's capital needs. The stock will be sold under a prospectus supplement filed on December 19, 2025, and an accompanying base prospectus. The offering can be made through negotiated transactions or as an "at-the-market offering" on the Nasdaq Global Select Market or other trading venues at prevailing market prices. H.C. Wainwright & Co., LLC will receive a 3.0% commission on gross proceeds. Net proceeds are intended for general corporate purposes, working capital, preclinical studies, clinical trials, and advancement of product candidates. The agreement includes customary representations, warranties, and indemnification. Sidley Austin LLP has provided a legality opinion regarding the common stock to be issued.